Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.

Iams WT, Shiuan E, Meador CB, Roth M, Bordeaux J, Vaupel C, Boyd KL, Summitt IB, Wang LL, Schneider JT, Warner JL, Zhao Z, Lovly CM.

J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463-0. doi: 10.1016/j.jtho.2019.05.042. [Epub ahead of print]

2.

Quantifying Drug Combination Synergy along Potency and Efficacy Axes.

Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, Lovly CM, Harris LA, Tyson DR, Quaranta V.

Cell Syst. 2019 Feb 27;8(2):97-108.e16. doi: 10.1016/j.cels.2019.01.003. Epub 2019 Feb 20.

PMID:
30797775
3.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM.

Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.

PMID:
30796031
4.

Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition.

Gallant JN, Sewell A, Almodovar K, Wang Q, Dahlman KB, Abramson RG, Kapp ME, Brown BT, Boyd KL, Gilbert J, Cohen DN, Yarbrough WG, Zhao Z, Lovly CM.

NPJ Precis Oncol. 2019 Feb 15;3:5. doi: 10.1038/s41698-019-0077-2. eCollection 2019.

5.

Correction: An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2019 Feb;9(2):303. doi: 10.1158/2159-8290.CD-18-1515. No abstract available.

PMID:
30737217
6.

Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.

Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL.

J Thorac Oncol. 2019 Feb;14(2):e29-e30. doi: 10.1016/j.jtho.2018.10.169. No abstract available.

PMID:
30683295
7.

Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases.

Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, Raymond CK, Horn L, Lovly CM.

J Thorac Oncol. 2019 Mar;14(3):e45-e48. doi: 10.1016/j.jtho.2018.11.031. Epub 2018 Dec 10. No abstract available.

8.

Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer.

Yu HA, Planchard D, Lovly CM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:726-739. doi: 10.1200/EDBK_201331. Review.

PMID:
30231382
9.

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Childress MA, Himmelberg SM, Chen H, Deng W, Davies MA, Lovly CM.

Mol Cancer Res. 2018 Nov;16(11):1724-1736. doi: 10.1158/1541-7786.MCR-18-0171. Epub 2018 Jul 12.

PMID:
30002191
10.

Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.

Iams WT, Lovly CM.

Cancer Discov. 2018 Jul;8(7):797-799. doi: 10.1158/2159-8290.CD-18-0489.

11.

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.

Fan PD, Narzisi G, Jayaprakash AD, Venturini E, Robine N, Smibert P, Germer S, Yu HA, Jordan EJ, Paik PK, Janjigian YY, Chaft JE, Wang L, Jungbluth AA, Middha S, Spraggon L, Qiao H, Lovly CM, Kris MG, Riely GJ, Politi K, Varmus H, Ladanyi M.

Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):E6030-E6038. doi: 10.1073/pnas.1717782115. Epub 2018 Jun 6.

12.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

13.

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L.

Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093/annonc/mdx703.

14.

Mechanisms of receptor tyrosine kinase activation in cancer.

Du Z, Lovly CM.

Mol Cancer. 2018 Feb 19;17(1):58. doi: 10.1186/s12943-018-0782-4. Review.

15.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

16.

Established, emerging and elusive molecular targets in the treatment of lung cancer.

Gallant JN, Lovly CM.

J Pathol. 2018 Apr;244(5):565-577. doi: 10.1002/path.5038. Epub 2018 Feb 14. Review.

PMID:
29344953
17.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

18.

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM.

J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23.

19.

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.

Oztan A, Fischer S, Schrock AB, Erlich RL, Lovly CM, Stephens PJ, Ross JS, Miller V, Ali SM, Ou SI, Raez LE.

Lung Cancer. 2017 Sep;111:84-87. doi: 10.1016/j.lungcan.2017.07.002. Epub 2017 Jul 8.

PMID:
28838405
20.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.

Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.

21.

Managing Resistance to EFGR- and ALK-Targeted Therapies.

Lovly CM, Iyengar P, Gainor JF.

Am Soc Clin Oncol Educ Book. 2017;37:607-618. doi: 10.14694/EDBK_176251. Review.

22.

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.

Ichihara E, Westover D, Meador CB, Yan Y, Bauer JA, Lu P, Ye F, Kulick A, de Stanchina E, McEwen R, Ladanyi M, Cross D, Pao W, Lovly CM.

Cancer Res. 2017 Jun 1;77(11):2990-3000. doi: 10.1158/0008-5472.CAN-16-2300. Epub 2017 Apr 17.

23.

An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.

Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE Jr, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.

Cancer Discov. 2017 Jun;7(6):575-585. doi: 10.1158/2159-8290.CD-16-1431. Epub 2017 Mar 8. Erratum in: Cancer Discov. 2019 Feb;9(2):303.

24.

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00146. Epub 2017 Dec 7.

25.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

26.
27.

My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information.

Kusnoor SV, Koonce TY, Levy MA, Lovly CM, Naylor HM, Anderson IA, Micheel CM, Chen SC, Ye F, Giuse NB.

AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:112-21. eCollection 2016.

28.

Major milestones in translational oncology.

Dragani TA, Castells A, Kulasingam V, Diamandis EP, Earl H, Iams WT, Lovly CM, Sedelaar JP, Schalken JA.

BMC Med. 2016 Jul 28;14(1):110. doi: 10.1186/s12916-016-0654-y.

29.

Melanoma driver mutations and immune therapy.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA.

Oncoimmunology. 2016 Mar 10;5(5):e1051299. doi: 10.1080/2162402X.2015.1051299. eCollection 2016 May.

30.

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML.

Clin Cancer Res. 2016 Oct 1;22(19):4837-4847. Epub 2016 Jun 1.

31.

Tumor Heterogeneity and Therapeutic Resistance.

Lovly CM, Salama AK, Salgia R.

Am Soc Clin Oncol Educ Book. 2016;35:e585-93. doi: 10.14694/EDBK_158808. Review.

32.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

33.

The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome.

Taylor AD, Micheel CM, Anderson IA, Levy MA, Lovly CM.

Transl Oncol. 2016 Apr;9(2):163-165. doi: 10.1016/j.tranon.2016.03.001.

34.

Guiding Oncology Patients Through the Maze of Precision Medicine.

Giuse NB, Kusnoor SV, Koonce TY, Naylor HM, Chen SC, Blasingame MN, Anderson IA, Micheel CM, Levy MA, Ye F, Lovly CM.

J Health Commun. 2016;21 Suppl 1:5-17. doi: 10.1080/10810730.2015.1131772.

35.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM.

Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582.

36.

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆.

Hames ML, Chen H, Iams W, Aston J, Lovly CM, Horn L.

Lung Cancer. 2016 Feb;92:29-34. doi: 10.1016/j.lungcan.2015.11.004. Epub 2015 Nov 10.

37.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovly CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J.

Cancer Res. 2016 Jan 15;76(2):305-18. doi: 10.1158/0008-5472.CAN-15-0717. Epub 2016 Jan 7.

38.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN.

J Clin Oncol. 2016 Jan 10;34(2):123-9. doi: 10.1200/JCO.2015.62.0138. Epub 2015 Oct 5.

39.

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade.

Iams WT, Lovly CM.

Clin Cancer Res. 2015 Oct 1;21(19):4270-7. doi: 10.1158/1078-0432.CCR-14-2518. Review.

40.

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Iams WT, Lovly CM.

Cancer J. 2015 Sep-Oct;21(5):378-82. doi: 10.1097/PPO.0000000000000142. Review.

41.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

42.

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.

Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM.

Cancer Discov. 2015 Nov;5(11):1155-63. doi: 10.1158/2159-8290.CD-15-0654. Epub 2015 Aug 18.

43.

Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.

Ichihara E, Lovly CM.

Cancer Discov. 2015 Jul;5(7):694-6. doi: 10.1158/2159-8290.CD-15-0616.

44.

Liquid biopsies reveal the dynamic nature of resistance mechanisms in solid tumors.

Meador CB, Lovly CM.

Nat Med. 2015 Jul;21(7):663-5. doi: 10.1038/nm.3899. No abstract available.

PMID:
26151324
45.

Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

Lovly CM.

Am Soc Clin Oncol Educ Book. 2015:e165-73. doi: 10.14694/EdBook_AM.2015.35.e165. Review.

46.

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Katayama R, Lovly CM, Shaw AT.

Clin Cancer Res. 2015 May 15;21(10):2227-35. doi: 10.1158/1078-0432.CCR-14-2791. Review.

47.

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA.

Cancer Immunol Res. 2015 Mar;3(3):288-295. doi: 10.1158/2326-6066.CIR-14-0207.

48.

Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM.

Cancer Immunol Res. 2015 May;3(5):464-9. doi: 10.1158/2326-6066.CIR-14-0217. Epub 2015 Feb 3.

49.

Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors.

Hornick JL, Sholl LM, Dal Cin P, Childress MA, Lovly CM.

Mod Pathol. 2015 May;28(5):732-9. doi: 10.1038/modpathol.2014.165. Epub 2015 Jan 23.

50.

Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.

Meador CB, Jin H, de Stanchina E, Nebhan CA, Pirazzoli V, Wang L, Lu P, Vuong H, Hutchinson KE, Jia P, Chen X, Eisenberg R, Ladanyi M, Politi K, Zhao Z, Lovly CM, Cross DA, Pao W.

Mol Cancer Ther. 2015 Feb;14(2):542-52. doi: 10.1158/1535-7163.MCT-14-0723. Epub 2014 Dec 4.

Supplemental Content

Loading ...
Support Center